United States · Platforms & data · MarketBeat
Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy
Detailed summary
Ocugen (NASDAQ:OCGN) expects pivotal data for its lead experimental gene therapy for retinitis pigmentosa in the first quarter of 2027, a milestone that could set up a regulatory filing later that year, CEO Shankar Musunuri said at a company presentation. The company is also advancing treatments fo
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)
